The Target of Rapamycin (TOR) is a conserved serine/threonine (ser/thr) kinase that
functions in two, distinct, multiprotein complexes called TORC1 and TORC2. Each complex …

PI3K/Akt/mTOR signaling regulates diverse cellular processes. Abnormal PI3K/Akt/mTOR
signaling is a characteristic feature of cancer. As such inhibition of PI3K/Akt/mTOR signaling …

Multiple myeloma (MM) is a plasma-cell malignancy which remains incurable despite the
recent emergence of multiple novel agents. Importantly, recent genetic and molecular …

The PI3K/AKT/mTOR signaling pathways are frequently dysregulated in multiple human
cancers, including multiple myeloma (MM), non‐Hodgkin lymphoma (NHL), and …

Multiple myeloma (MM) is an incurable hematopoietic neoplasm derived from plasma cells,
and existing in the bone marrow. Recent developments in the field of myeloma onco‐biology …

Mechanistic target of rapamycin (mTOR) is the kinase subunit of two structurally and
functionally distinct large multiprotein complexes, referred to as mTOR complex 1 (mTORC1) …

Multiple myeloma (MM), a cancer of terminally differentiated plasma cells, is the second
most common hematological malignancy. The disease is characterized by the accumulation …

Neuroblastoma is one of the most common pediatric solid tumors that threaten the health of
children, accounting for about 15% of childhood cancer-related mortality in the United …

The evolutionarily conserved mechanistic target of rapamycin (mTOR) forms two functionally
distinct complexes, mTORC1 and mTORC2. mTORC1, consisting of mTOR, raptor, and …

Introduction: Significant advances have been made during the last two decades in terms of
new therapeutic options but also of innovative approaches to diagnosis and management of …